Novartis reaffirms that respiratory research is to remain in Horsham, UK

According to a newspaper report, Novartis has confirmed that it will retain its respiratory disease research center in Horsham, UK, with 440 employees. The company will sell a portion of the site and plans to invest approximately £5 million to renovate some of the remaining buildings.

In March 2011, Novartis announced significant personnel reductions at the site but stated that respiratory research would stay; however, local officials were apparently concerned that the research center was still in danger.

Manufacturing at the site is scheduled to end in 2013.

Read the West Sussex County Times article.

Share

published on

May 10-May 14RDD 2026, Phoenix, AZ, USA

May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA

May 17-May 20: ATS International Conference 2026, Orlando, FL, USA

June 10SMI.London 2026, London, UK

July 13-July 162026 ISAM Congress, Taipei, Taiwan